Medscape (12/14, Brooks, Subscription Publication) reports a new study now “provides more evidence that antipsychotics that raise prolactin levels are tied to a significantly increased risk for breast cancer.” After identifying “914 cases of invasive breast cancer among 540,737 women,” investigators concluded that “the relative risk for breast cancer was 62% higher in women who took category 1 antipsychotic medications associated with high prolactin levels.” These medications “include haloperidol (Haldol), paliperidone (Invega), and risperidone (Risperdal).” What’s more, “the risk was 54% higher in those taking category 2 antipsychotics that have mid-range effects on prolactin,” such as “iloperidone (Fanapt), lurasidone (Latuda), and olanzapine (Zyprexa).” The findings were published online Dec. 3 in the Journal of Clinical Psychopharmacology.
Related Links:
— Medscape (requires login and subscription)